List of Lorbrena drug patents
Lorbrena is owned by Pfizer.
Lorbrena contains Lorlatinib.
Lorbrena has a total of 4 drug patents out of which 0 drug patents have expired.
Lorbrena was authorised for market use on 02 November, 2018.
Lorbrena is available in tablet;oral dosage forms.
Lorbrena can be used as treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test.
Drug patent challenges can be filed against Lorbrena from 2022-11-02.
The generics of Lorbrena are possible to be released after 04 October, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(9 years from now) | |
| US10420749 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
| US11299500 | PFIZER | Crystalline form of lorlatinib free base hydrate |
Oct, 2038
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020376 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 2, 2023 |
| Orphan Drug Exclusivity (ODE) | Mar 3, 2028 |
| New Indication (I) | Mar 3, 2024 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: 2022-11-02
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceriti...
Dosage: TABLET;ORAL
LORBRENA family patents
12
United States
4
Japan
4
European Union
3
Australia
3
IB
3
Korea, Republic of
3
Canada
3
Singapore
3
Russia
3
Argentina
3
China
3
Mexico
3
Brazil
3
Hungary
3
Taiwan
2
Denmark
2
Spain
2
Portugal
2
Poland
2
Hong Kong
2
Slovenia
2
Lithuania
1
Colombia
1
Luxembourg
1
EA
1
Israel
1
Croatia
1
Dominican Republic
1
Moldova, Republic of
1
Netherlands
1
New Zealand
1
Tunisia
1
Uruguay
1
Peru
1
Costa Rica
1
Nicaragua
1
Chile
1
ME
1
Cyprus
1
Ukraine
1
Philippines
1
Morocco
1
Norway
1
Guatemala
1
Georgia
1
Cuba
1
South Africa
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic